COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN

被引：0
|
作者：
Arriola, E. [1 ]
Batteson, R. [2 ]
Hook, E. [2 ]
Wheat, H. [2 ]
Vioix, H. [3 ]
Morros, M. [4 ]
Aguila, M. [4 ]
de los Santos Real, H. [5 ]
Soberon S, Fernandez [5 ]
Brines, M. [5 ]
Vazquez, S. [6 ]
机构：
[1] Hosp Mar, Barcelona, Spain
[2] Delta Hat Ltd, Nottingham, England
[3] Merck KGaA, Healthcare Business, Darmstadt, HE, Germany
[4] Adelphi Targis, Barcelona, Spain
[5] Merck SLU, Madrid, Spain
[6] Hosp Univ Lucus Augusti, Lugo, Spain
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE146
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [41] Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
    Ahn, Linda
    Alexander, Terri
    Vlassak, Soetkin
    Berghoff, Karin
    Lemmens, Liesbeth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (05) : 543 - 551
  • [42] Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report
    Kleemiss, Moritz
    Mueller, Christa E.
    Schneider, Marion
    Strotmann, Rainer
    Orlowski, Katrin
    Goteti, Kosalaram
    Yanik, Mert
    Brossart, Peter
    Bauernfeind, Franz-Georg
    CLINICAL LUNG CANCER, 2024, 25 (06) : 577 - 580
  • [43] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM
    Moeremans, K.
    Van Bellinghen, L.
    De Celle, T.
    Quintens, B.
    Paracha, N.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [44] Phase II trial of the c-Met inhibitor tepotinib in patients with advanced non-small cell lung cancer harboring MET exon 14-skipping mutations
    Felip, Enriqueta
    Veillon, Remi
    Viteri, Santiago
    Scheele, Jurgen
    Bruns, Rolf
    Paik, Paul K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [45] Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
    Blaszkowska, M.
    Specht-Szwoch, Z.
    Dziadziuszko, R.
    ESMO OPEN, 2022, 7 (02)
  • [46] Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
    Brazel, Danielle
    Zhang, Shannon
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 33 - 45
  • [47] Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
    Gong, Jinhong
    Su, Dan
    Shang, Jingjing
    Xu, Shan
    Tang, Lidan
    Sun, Zhiqiang
    Liu, Guangjun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice
    Ho, C.
    Wong, S.
    Hatswell, A.
    Slater, R.
    Vioix, H.
    Chouaid, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1087 - S1088
  • [49] Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance
    Chen, Shengnan
    Hu, Tao
    Zhao, Jikai
    Zhu, Qian
    Wang, Jin
    Huang, Zhan
    Xiang, Chan
    Zhao, Ruiying
    Zhu, Changbin
    Lu, Shun
    Han, Yuchen
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [50] Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study
    Ferreira, Marion
    Swalduz, Aurelie
    Greillier, Laurent
    du Rusquec, Pauline
    Curcio, Hubert
    Raimbourg, Judith
    Toffart, Anne-Claire
    Gounant, Valerie
    Couraudi, Sebastien
    De Chabot, Gonzague
    Friard, Sylvie
    Hureaux, Jose
    Jeannin, Gaelle
    Odier, Luc
    Ricordel, Charles
    Wislez, Marie
    Descarpentries, Clotilde
    Herbreteau, Guillaume
    Missy, Pascale
    Morin, Franck
    Westeel, Virginie
    Cortot, Alexis B.
    LUNG CANCER, 2024, 196
12345